Event Event

American Society of Hematology 2025

December 6 - December 9, 2025

Orlando, Fla.

Request a meeting

ASH Annual Meeting represents 30,000 Hematology professionals from every speciality, 5,000 abstracts and 275 exhibitors. 

As the world’s largest professional society of clinicians and scientists dedicated to conquering blood diseases, ASH seeks to expand the availability of hematologic care while promoting the highest standards of excellence in hematology research, training, and practice. 

Visit us at booth #260

Scott Smith, M.D., Ph.D.

Franchise Head, Hematology

Saturday, Dec. 6 from 6-8p.m.

Poster title: Infections following combined therapy with a GPRC5DxCD3 bispecific antibody, talquetamab, and an Interleukin-6 receptor inhibitor, tocilizumab, in multiple myeloma patients

Dikshya Shrestha

Senior Director, Pharmaceutical and Medical Services

Saturday, Dec. 6 from 5:30-7:30p.m.

Poster title: Hematologic predictors of serious infection and impact of serious infection on long-term mortality in AML Patients: Insights from a Propensity-Matched Real-World Cohorts

Heidi Cho, M.D.

Medical Operations Principal, Hematology

Sunday, Dec. 7 from 6-8p.m.
Poster title: Cyclophosphamide versus Methotrexate for Treating Large Granular Lymphocyte Leukemia: Real-World Data Insights

Monday, Dec. 8 from 6-8p.m.
Poster title: Association Between Pre-existing Mental Health History and Higher Risk of Mental Health Outcomes Post-CAR-T Therapy in Patients with Hematologic Malignancies

Kristy Pahl

Medical Director, Therapeutic Area Lead

Monday, Dec. 8 from 6-8p.m.

Poster title: Real world evidence of treatment patterns in Hereditary Hemorrhagic Telangiectasia

Nancy Lunney, MA, LPA

HSP Project Director and Program Leader, Cell and Gene Therapy Center of Excellence

Monday, Dec. 8 from 6-8p.m.

Poster title: Risk of Bleeding in Chronic Lymphocytic Leukemia Patients in Remission Treated with Covalent Bruton Tyrosine Kinase Inhibitors and Contemporary Anticoagulant or Antiplatelet Drugs: Real-World Data Analysis

Maria Ahmad

Senior Medical Director, Therapeutic Area Lead

Monday, Dec. 8 from 6-8p.m.

Poster title: Incidence and Risk Factors of Hemophagocytic Lymphohistiocytosis after Bispecific Antibody Therapy in Hematologic Malignancies: Insights from a Global Real-World Cohort 

Request a meeting

Are you interested in meeting with our experts at this event? Please fill out the form below, and we'll contact you with more details.